Drugs / ABL-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06850324 | Jul 2025 → Jun 2027 expected | atherosclerosis | Ruud van Heeswijk | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03463551 | Sep 2018 → Sep 2019 | ischemic stroke | NHS Greater Glasgow and Clyde | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-02-28 | Aurum Biosciences Ltd | Regulatory Innovation passport takes Scottish company’s acute stroke treatment to next level aurumbiosciences.com ↗
The Innovation Passport was awarded by the ILAP steering group which includes the Medicines and Healthcare products Regulatory Agency (MHRA), National Institute for Health and Care Excellence (NICE), and the Scottish Medicines Consortium (SMC) |
| 2019-11-22 | Aurum Biosciences Ltd | Results ABL-101 Found to be a Promising Candidate for Use in Inflammation Imaging aurumbiosciences.com ↗
This pre-clinical work, which was conducted on a 3T clinical scanner along with higher field systems, demonstrated that ABL-101 is a very promising contrast agent for inflammation and cell tracking. |
| 2018-06-04 | Aurum Biosciences Ltd | Results Aurum Publishes Paper on ABL-101 Technology aurumbiosciences.com ↗
Additionally Aurum collected data suggesting potential therapeutic benefit to animals that had been treated with ABL-101 technology. |
| 2017-12-18 | Aurum Biosciences Ltd | Regulatory Aurum Biosciences receives UK regulatory approval for a Phase 2 trial of ABL-101 in stroke patients aurumbiosciences.com ↗
Aurum Biosciences Ltd ( olliet39.sg-host.com/ ), a Glasgow-based biopharmaceutical company developing a novel, first-in-class stroke therapy and diagnostic, has received approval from the UK regulatory authority (MHRA) for a Phase 2 clinical trial due to start in Q1 2018. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-02-28 | Aurum Biosciences Ltd | Innovation passport takes Scottish company’s acute stroke treatment to next level aurumbiosciences.com ↗ |
| 2019-11-22 | Aurum Biosciences Ltd | ABL-101 Found to be a Promising Candidate for Use in Inflammation Imaging aurumbiosciences.com ↗ |
| 2018-06-04 | Aurum Biosciences Ltd | Aurum Publishes Paper on ABL-101 Technology aurumbiosciences.com ↗ |
| 2017-12-18 | Aurum Biosciences Ltd | Aurum Biosciences receives UK regulatory approval for a Phase 2 trial of ABL-101 in stroke patients aurumbiosciences.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABL-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03463551 ↗ |
| Modality | Diagnostic / imaging agent | “In this study, the investigators therefore evaluate a new marker, the perfluorocarbon ABL-101, for non-invasive imaging of inflammation in atherosclerotic plaque.” NCT06850324 ↗ |
| Route | Intravenous | “ABL-101 is provided as a sterile phospholipid-based emulsion for intravenous administration.” NCT03463551 ↗ |